Procaps Group S.A Key Executives
This section highlights Procaps Group S.A's key executives, including their titles and compensation details.
Find Contacts at Procaps Group S.A
(Showing 0 of )
Procaps Group S.A Earnings
This section highlights Procaps Group S.A's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q2 | 2023 | 2023-09-05 | $0.06 | $0.27 |
| Read Transcript | Q1 | 2023 | 2023-05-15 | N/A | N/A |
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
$1.01
Stock Price
$113.95M
Market Cap
5.50K
Employees
Luxembourg City, None
Location
Financial Statements
Access annual & quarterly financial statements for Procaps Group S.A, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Revenue | $409.92M | $409.74M | $331.47M | $324.79M |
| Cost of Revenue | $170.35M | $174.03M | $140.15M | $142.29M |
| Gross Profit | $239.57M | $235.71M | $191.31M | $182.50M |
| Gross Profit Ratio | 58.44% | 57.50% | 57.72% | 56.19% |
| Research and Development Expenses | $- | $3.06M | $- | $- |
| General and Administrative Expenses | $105.91M | $82.19M | $58.63M | $60.26M |
| Selling and Marketing Expenses | $93.57M | $83.06M | $69.63M | $84.81M |
| Selling General and Administrative Expenses | $199.48M | $165.24M | $128.26M | $145.07M |
| Other Expenses | $- | $-72.08M | $-844.00K | $273.00K |
| Operating Expenses | $187.25M | $165.24M | $128.26M | $145.07M |
| Cost and Expenses | $357.60M | $339.27M | $268.41M | $287.36M |
| Interest Income | $- | $85.32M | $52.63M | $41.54M |
| Interest Expense | $25.76M | $85.32M | $52.63M | $41.54M |
| Depreciation and Amortization | $16.84M | $15.11M | $16.48M | $16.47M |
| EBITDA | $104.03M | $6.59M | $76.83M | $52.73M |
| EBITDA Ratio | 25.38% | 2.40% | 23.18% | 16.24% |
| Operating Income | $52.32M | $-5.29M | $60.35M | $36.26M |
| Operating Income Ratio | 12.76% | -1.29% | 18.21% | 11.17% |
| Total Other Income Expenses Net | $386.00K | $-156.85M | $-59.50M | $-46.24M |
| Income Before Tax | $52.71M | $-87.16M | $849.00K | $-9.98M |
| Income Before Tax Ratio | 12.86% | -21.27% | 0.26% | -3.07% |
| Income Tax Expense | $10.17M | $13.71M | $11.30M | $7.04M |
| Net Income | $42.54M | $-100.86M | $-10.45M | $-17.01M |
| Net Income Ratio | 10.38% | -24.62% | -3.15% | -5.24% |
| EPS | $0.42 | $-1.03 | $-0.09 | $-0.15 |
| EPS Diluted | $0.42 | $-1.03 | $-0.09 | $-0.15 |
| Weighted Average Shares Outstanding | 101.11M | 97.93M | 112.82M | 112.82M |
| Weighted Average Shares Outstanding Diluted | 101.11M | 98.14M | 112.82M | 112.82M |
| SEC Filing | Source | Source | Source | Source |
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $118.41M | $110.06M | $84.16M | $101.47M | $110.40M | $112.42M | $85.63M | $126.54M | $106.83M | $98.94M | $77.44M | $118.15M | $79.31M | $81.90M | $52.11M | $81.20M | $81.20M | $81.20M | $81.20M |
| Cost of Revenue | $50.01M | $48.87M | $38.10M | $49.21M | $42.84M | $39.79M | $38.51M | $50.88M | $44.58M | $40.82M | $37.76M | $50.02M | $31.52M | $36.88M | $21.72M | $35.57M | $35.57M | $35.57M | $35.57M |
| Gross Profit | $68.40M | $61.19M | $46.06M | $52.26M | $67.56M | $72.63M | $47.12M | $75.66M | $62.25M | $58.12M | $39.69M | $68.13M | $47.79M | $45.01M | $30.39M | $45.62M | $45.62M | $45.62M | $45.62M |
| Gross Profit Ratio | 57.80% | 55.60% | 54.70% | 51.50% | 61.20% | 64.60% | 55.00% | 59.80% | 58.30% | 58.70% | 51.20% | 57.66% | 60.25% | 54.96% | 58.31% | 56.19% | 56.19% | 56.19% | 56.19% |
| Research and Development Expenses | $- | $- | $- | $2.73M | $- | $- | $- | $3.06M | $- | $- | $1.80M | $3.04M | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $25.78M | $24.60M | $22.12M | $28.17M | $24.34M | $28.84M | $24.56M | $17.52M | $21.01M | $23.08M | $20.58M | $14.77M | $14.37M | $14.26M | $15.22M | $36.27M | $36.27M | $36.27M | $36.27M |
| Selling and Marketing Expenses | $29.44M | $21.50M | $20.67M | $21.87M | $25.88M | $25.66M | $20.16M | $21.87M | $22.84M | $18.87M | $19.48M | $16.28M | $19.23M | $15.93M | $18.18M | $21.20M | $21.20M | $21.20M | $21.20M |
| Selling General and Administrative Expenses | $55.22M | $46.10M | $42.79M | $50.04M | $50.21M | $54.51M | $44.71M | $39.38M | $43.85M | $41.95M | $40.06M | $31.05M | $33.60M | $30.20M | $33.41M | $57.47M | $57.47M | $57.47M | $57.47M |
| Other Expenses | $- | $19.52M | $3.96M | $13.15M | $-9.71M | $-8.63M | $389.00K | $-68.91M | $-1.11M | $-1.54M | $98.00K | $4.56M | $-1.67M | $1.66M | $-5.40M | $68.25K | $68.25K | $68.25K | $68.25K |
| Operating Expenses | $55.22M | $46.14M | $42.79M | $50.04M | $50.21M | $54.51M | $44.71M | $39.38M | $43.85M | $41.95M | $40.06M | $31.05M | $33.60M | $30.20M | $33.41M | $57.54M | $57.54M | $57.54M | $57.54M |
| Cost and Expenses | $105.23M | $95.01M | $80.89M | $99.25M | $93.06M | $94.30M | $83.22M | $90.26M | $88.43M | $82.77M | $77.81M | $81.07M | $65.13M | $67.08M | $55.13M | $71.84M | $71.84M | $71.84M | $71.84M |
| Interest Income | $- | $10.89M | $9.07M | $8.11M | $6.29M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $11.65M | $10.58M | $8.80M | $31.09M | $22.75M | $18.79M | $- | $- | $50.65M | $14.35M | $13.40M | $- | $14.24M | $12.21M | $13.31M | $10.39M | $10.39M | $10.39M | $10.39M |
| Depreciation and Amortization | $4.98M | $4.32M | $3.71M | $4.46M | $4.01M | $4.87M | $3.50M | $1.75M | $4.46M | $5.08M | $3.83M | $4.61M | $3.91M | $4.39M | $3.56M | $-1.47M | $-1.47M | $-1.47M | $-1.47M |
| EBITDA | $28.07M | $37.72M | $10.29M | $30.47M | $21.36M | $1.86M | $5.73M | $-37.18M | $21.75M | $19.70M | $2.92M | $37.52M | $16.42M | $20.87M | $420.03K | $100.80K | $7.89M | $7.89M | $7.89M |
| EBITDA Ratio | 23.70% | 34.27% | 12.22% | 44.40% | 19.35% | 12.78% | 6.69% | -24.58% | 20.36% | 19.20% | 4.42% | 31.76% | 20.71% | 25.49% | -9.33% | 9.72% | 9.72% | 9.72% | 9.72% |
| Operating Income | $13.18M | $33.40M | $6.58M | $40.59M | $17.35M | $9.50M | $2.23M | $-32.85M | $18.40M | $16.16M | $-372.00K | $37.08M | $14.18M | $14.82M | $-3.02M | $9.36M | $9.36M | $9.36M | $9.36M |
| Operating Income Ratio | 11.13% | 30.35% | 7.82% | 40.01% | 15.71% | 8.45% | 2.60% | -25.96% | 17.22% | 16.34% | -0.48% | 31.38% | 17.88% | 18.09% | -5.80% | 11.52% | 11.52% | 11.52% | 11.52% |
| Total Other Income Expenses Net | $-1.75M | $22.85M | $5.61M | $-31.09M | $13.04M | $-27.40M | $19.71M | $-74.43M | $-51.76M | $-15.89M | $-12.97M | $-14.00M | $-15.90M | $-10.55M | $-5.71M | $587.27K | $-11.85M | $-11.85M | $-11.85M |
| Income Before Tax | $11.43M | $37.94M | $8.88M | $9.50M | $30.39M | $-9.29M | $22.11M | $-38.93M | $-33.36M | $274.00K | $-15.14M | $20.04M | $-1.72M | $4.27M | $-21.74M | $-2.49M | $-2.49M | $-2.49M | $-2.49M |
| Income Before Tax Ratio | 9.66% | 34.47% | 10.55% | 9.36% | 27.52% | -8.27% | 25.83% | -30.77% | -31.23% | 0.28% | -19.56% | 16.96% | -2.17% | 5.21% | -41.72% | -3.07% | -3.07% | -3.07% | -3.07% |
| Income Tax Expense | $3.23M | $10.98M | $2.26M | $-934.00K | $7.81M | $-2.37M | $5.67M | $7.36M | $3.57M | $882.00K | $1.89M | $10.60M | $-751.00K | $-4.39M | $5.84M | $1.76M | $1.76M | $1.76M | $1.76M |
| Net Income | $8.19M | $26.95M | $6.62M | $10.43M | $22.58M | $-6.92M | $16.45M | $-46.29M | $-36.60M | $-649.00K | $-17.32M | $9.45M | $-969.00K | $8.66M | $-27.58M | $-4.25M | $-4.25M | $-4.25M | $-4.25M |
| Net Income Ratio | 6.92% | 24.49% | 7.87% | 10.28% | 20.45% | -6.15% | 19.21% | -36.58% | -34.26% | -0.66% | -22.36% | 7.99% | -1.22% | 10.57% | -52.93% | -5.24% | -5.24% | -5.24% | -5.24% |
| EPS | $0.08 | $0.27 | $0.07 | $0.10 | $0.22 | $-0.07 | $0.16 | $-0.47 | $-0.38 | $-0.01 | $-0.18 | $0.10 | $-0.01 | $0.09 | $-0.28 | $-0.04 | $-0.04 | $-0.04 | $-0.04 |
| EPS Diluted | $0.08 | $0.27 | $0.07 | $0.10 | $0.22 | $-0.07 | $0.16 | $-0.47 | $-0.38 | $-0.01 | $-0.15 | $0.08 | $-0.01 | $0.08 | $-0.24 | $-0.04 | $-0.04 | $-0.04 | $-0.04 |
| Weighted Average Shares Outstanding | 102.42M | 99.83M | 94.59M | 101.11M | 101.11M | 98.84M | 101.11M | 98.14M | 97.14M | 112.82M | 97.28M | 97.62M | 97.28M | 97.28M | 97.28M | 97.62M | 97.62M | 97.62M | 97.62M |
| Weighted Average Shares Outstanding Diluted | 102.42M | 99.83M | 94.59M | 101.11M | 102.64M | 98.84M | 101.11M | 98.14M | 97.28M | 112.82M | 112.82M | 112.82M | 112.82M | 112.82M | 112.82M | 112.82M | 112.82M | 112.82M | 112.82M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Cash and Cash Equivalents | $43.00M | $72.11M | $4.23M | $2.04M |
| Short Term Investments | $- | $- | $- | $- |
| Cash and Short Term Investments | $43.00M | $72.11M | $4.23M | $2.04M |
| Net Receivables | $153.26M | $103.19M | $88.50M | $98.11M |
| Inventory | $96.83M | $79.43M | $64.28M | $65.00M |
| Other Current Assets | $4.34M | $33.67M | $27.68M | $7.29M |
| Total Current Assets | $297.44M | $298.06M | $184.70M | $172.45M |
| Property Plant Equipment Net | $112.98M | $112.81M | $113.53M | $113.21M |
| Goodwill | $5.79M | $6.80M | $6.86M | $7.02M |
| Intangible Assets | $32.21M | $30.17M | $27.58M | $23.20M |
| Goodwill and Intangible Assets | $38.00M | $36.97M | $34.45M | $30.22M |
| Long Term Investments | $1.72M | $2.70M | $3.22M | $2.52M |
| Tax Assets | $6.97M | $7.07M | $21.77M | $16.21M |
| Other Non-Current Assets | $3.08M | $4.53M | $1.87M | $3.11M |
| Total Non-Current Assets | $162.74M | $164.08M | $174.84M | $165.28M |
| Other Assets | $- | $- | $- | $- |
| Total Assets | $460.19M | $462.13M | $359.54M | $337.73M |
| Account Payables | $81.48M | $70.17M | $84.48M | $94.21M |
| Short Term Debt | $257.52M | $84.50M | $114.78M | $99.97M |
| Tax Payables | $6.13M | $11.76M | $9.39M | $7.54M |
| Deferred Revenue | $- | $35.92M | $29.32M | $45.31M |
| Other Current Liabilities | $23.24M | $21.54M | $30.98M | $46.75M |
| Total Current Liabilities | $368.37M | $187.96M | $239.63M | $248.48M |
| Long Term Debt | $28.41M | $200.61M | $339.74M | $320.46M |
| Deferred Revenue Non-Current | $- | $23.11M | $12.16M | $- |
| Deferred Tax Liabilities Non-Current | $7.82M | $6.07M | $18.89M | $7.66M |
| Other Non-Current Liabilities | $57.46M | $105.83M | $3.80M | $12.74M |
| Total Non-Current Liabilities | $93.69M | $312.51M | $374.59M | $333.20M |
| Other Liabilities | $- | $- | $- | $- |
| Total Liabilities | $462.06M | $500.48M | $614.22M | $581.67M |
| Preferred Stock | $- | $- | $- | $- |
| Common Stock | $1.01M | $1.01M | $2.00M | $2.00M |
| Retained Earnings | $-391.51M | $-431.06M | $-327.34M | $-305.63M |
| Accumulated Other Comprehensive Income Loss | $11.88M | $14.97M | $15.48M | $4.93M |
| Other Total Stockholders Equity | $377.68M | $377.68M | $54.41M | $83.09M |
| Total Stockholders Equity | $-941.00K | $-37.40M | $-255.46M | $-244.29M |
| Total Equity | $-1.88M | $-38.34M | $-254.68M | $-243.95M |
| Total Liabilities and Stockholders Equity | $460.19M | $462.13M | $359.54M | $337.73M |
| Minority Interest | $-937.00K | $-940.00K | $777.00K | $346.00K |
| Total Liabilities and Total Equity | $460.19M | $462.13M | $359.54M | $337.73M |
| Total Investments | $1.72M | $2.70M | $3.22M | $2.52M |
| Total Debt | $285.94M | $253.37M | $454.52M | $420.44M |
| Net Debt | $242.93M | $181.25M | $450.29M | $418.39M |
Balance Sheet Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $17.56M | $11.54M | $23.03M | $43.00M | $27.21M | $37.55M | $65.64M | $72.11M | $100.19M | $7.70M | $7.60M | $4.23M | $1.06M | $1.06M | $-2.04M | $510.50K | $510.50K | $510.50K | $510.50K |
| Short Term Investments | $8.27M | $8.43M | $- | $- | $- | $- | $- | $- | $- | $- | $8.46M | $- | $- | $- | $4.08M | $- | $- | $- | $- |
| Cash and Short Term Investments | $17.56M | $19.97M | $23.03M | $43.00M | $27.21M | $37.55M | $65.64M | $72.11M | $100.19M | $7.70M | $7.60M | $4.23M | $1.06M | $1.06M | $2.04M | $510.50K | $510.50K | $510.50K | $510.50K |
| Net Receivables | $170.87M | $169.59M | $108.53M | $153.26M | $113.69M | $105.52M | $95.28M | $103.19M | $113.42M | $86.66M | $96.16M | $88.50M | $28.96M | $28.96M | $- | $26.33M | $26.33M | $26.33M | $26.33M |
| Inventory | $98.24M | $103.47M | $99.15M | $96.83M | $100.36M | $99.23M | $98.34M | $79.43M | $76.98M | $68.38M | $61.87M | $64.28M | $16.07M | $16.07M | $16.07M | $16.25M | $16.25M | $16.25M | $16.25M |
| Other Current Assets | $11.68M | $10.95M | $38.13M | $4.34M | $62.09M | $54.93M | $50.67M | $33.67M | $22.27M | $38.52M | $19.66M | $27.68M | $186.47K | $90.00K | $- | $24.50K | $24.50K | $24.50K | $24.50K |
| Total Current Assets | $298.35M | $295.55M | $268.85M | $297.44M | $303.36M | $297.23M | $309.94M | $298.06M | $312.87M | $201.26M | $185.29M | $184.70M | $46.18M | $46.18M | $2.04M | $43.11M | $43.11M | $43.11M | $43.11M |
| Property Plant Equipment Net | $137.36M | $132.60M | $121.53M | $112.98M | $115.17M | $120.42M | $118.19M | $112.81M | $107.90M | $105.81M | $104.51M | $113.53M | $28.38M | $28.38M | $28.38M | $28.30M | $28.30M | $28.30M | $28.30M |
| Goodwill | $5.79M | $5.79M | $5.79M | $5.79M | $6.67M | $6.76M | $6.86M | $6.80M | $6.85M | $6.87M | $1.70M | $6.86M | $1.72M | $1.72M | $1.72M | $1.75M | $1.75M | $1.75M | $1.75M |
| Intangible Assets | $41.31M | $39.16M | $34.38M | $32.21M | $31.28M | $31.88M | $32.71M | $30.17M | $24.75M | $25.18M | $7.54M | $27.58M | $6.90M | $6.90M | $6.90M | $5.80M | $5.80M | $5.80M | $5.80M |
| Goodwill and Intangible Assets | $47.10M | $44.95M | $40.16M | $38.00M | $37.95M | $38.64M | $39.57M | $36.97M | $31.61M | $32.05M | $9.24M | $34.45M | $8.61M | $8.61M | $8.61M | $7.56M | $7.56M | $7.56M | $7.56M |
| Long Term Investments | $6.16M | $8.19M | $1.94M | $1.72M | $2.42M | $2.57M | $2.60M | $2.70M | $2.92M | $3.48M | $3.06M | $3.22M | $615.00K | $615.00K | $615.00K | $347.50K | $347.50K | $347.50K | $347.50K |
| Tax Assets | $7.40M | $7.01M | $6.71M | $6.97M | $7.84M | $7.58M | $7.89M | $7.07M | $6.67M | $6.75M | $7.07M | $21.77M | $5.44M | $5.44M | $5.44M | $4.05M | $4.05M | $4.05M | $4.05M |
| Other Non-Current Assets | $2.19M | $2.42M | $2.53M | $3.08M | $4.45M | $3.75M | $5.07M | $4.53M | $2.78M | $2.69M | $26.03M | $1.87M | $657.75K | $657.75K | $-45.09M | $1.06M | $1.06M | $1.06M | $1.06M |
| Total Non-Current Assets | $200.20M | $195.17M | $172.87M | $162.74M | $167.81M | $172.96M | $173.33M | $164.08M | $151.88M | $150.77M | $149.91M | $174.84M | $43.71M | $43.71M | $-2.04M | $41.32M | $41.32M | $41.32M | $41.32M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $89.88M | $- | $- | $- | $- |
| Total Assets | $498.55M | $490.72M | $441.72M | $460.19M | $471.17M | $470.19M | $483.27M | $462.13M | $464.75M | $352.03M | $335.20M | $359.54M | $89.88M | $89.88M | $89.88M | $84.43M | $84.43M | $84.43M | $84.43M |
| Account Payables | $89.76M | $85.97M | $79.91M | $81.48M | $95.27M | $90.58M | $90.28M | $70.17M | $132.46M | $113.12M | $106.58M | $84.48M | $21.12M | $21.12M | $21.12M | $23.55M | $23.55M | $23.55M | $23.55M |
| Short Term Debt | $69.24M | $118.68M | $135.11M | $257.59M | $83.07M | $91.29M | $100.10M | $84.50M | $116.71M | $95.26M | $102.20M | $114.78M | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $23.62M | $21.84M | $7.41M | $6.13M | $21.08M | $10.85M | $18.32M | $11.76M | $14.25M | $8.77M | $12.95M | $9.39M | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $25.96M | $- | $- | $- | $- | $- | $35.92M | $21.61M | $8.77M | $12.95M | $29.32M | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $20.31M | $-8.57M | $11.03M | $23.18M | $20.03M | $58.00K | $12.41M | $21.54M | $-8.29M | $-5.01M | $20.84M | $30.98M | $38.79M | $38.79M | $38.79M | $38.57M | $38.57M | $38.57M | $38.57M |
| Total Current Liabilities | $202.93M | $243.88M | $233.46M | $368.37M | $219.45M | $192.79M | $221.11M | $187.96M | $276.75M | $229.68M | $242.57M | $239.63M | $59.91M | $59.91M | $59.91M | $62.12M | $62.12M | $62.12M | $62.12M |
| Long Term Debt | $220.68M | $204.60M | $183.99M | $28.41M | $205.45M | $202.56M | $168.63M | $200.61M | $101.93M | $381.92M | $350.14M | $339.74M | $84.93M | $84.93M | $84.93M | $80.12M | $80.12M | $80.12M | $80.12M |
| Deferred Revenue Non-Current | $- | $4.46M | $- | $- | $- | $- | $- | $23.11M | $45.14M | $- | $- | $12.16M | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $3.37M | $3.40M | $6.62M | $7.82M | $2.41M | $6.70M | $6.39M | $6.07M | $1.45M | $2.44M | $4.02M | $18.89M | $4.72M | $4.72M | $4.72M | $1.91M | $1.91M | $1.91M | $1.91M |
| Other Non-Current Liabilities | $33.12M | $2.35M | $12.48M | $57.46M | $54.38M | $97.72M | $113.19M | $105.83M | $3.17M | $16.89M | $14.68M | $3.80M | $3.99M | $3.99M | $3.99M | $1.27M | $1.27M | $1.27M | $1.27M |
| Total Non-Current Liabilities | $257.17M | $214.81M | $203.08M | $93.69M | $262.23M | $306.98M | $281.82M | $312.51M | $151.70M | $398.81M | $368.84M | $374.59M | $93.65M | $93.65M | $93.65M | $83.30M | $83.30M | $83.30M | $83.30M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $460.10M | $458.69M | $436.55M | $462.06M | $481.68M | $499.76M | $502.93M | $500.48M | $428.44M | $628.50M | $611.41M | $614.22M | $153.55M | $153.55M | $153.55M | $145.42M | $145.42M | $145.42M | $145.42M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $27.00K | $- | $- | $- | $- | $- | $81.34M | $- | $- | $- | $- |
| Common Stock | $1.01M | $1.01M | $1.01M | $1.01M | $1.01M | $1.01M | $1.01M | $1.01M | $1.13M | $2.00M | $2.00M | $2.00M | $500.25K | $500.25K | $500.25K | $500.25K | $500.25K | $500.25K | $500.25K |
| Retained Earnings | $-354.23M | $-362.43M | $-384.89M | $-391.51M | $-401.95M | $-424.53M | $-417.61M | $-431.06M | $-233.27M | $-344.98M | $-344.37M | $-327.34M | $-81.84M | $-81.84M | $-81.84M | $-76.41M | $-76.41M | $-76.41M | $-76.41M |
| Accumulated Other Comprehensive Income Loss | $15.88M | $16.71M | $12.31M | $11.88M | $13.69M | $17.20M | $20.20M | $14.97M | $11.57M | $11.01M | $10.69M | $15.48M | $-11.24M | $-11.24M | $-244.29M | $-9.92M | $-9.92M | $-9.92M | $-9.92M |
| Other Total Stockholders Equity | $376.73M | $377.52M | $377.68M | $377.68M | $377.68M | $377.68M | $423.42M | $377.68M | $295.58M | $94.30M | $54.41M | $54.41M | $28.91M | $28.91M | $82.18M | $24.84M | $24.84M | $24.84M | $24.84M |
| Total Stockholders Equity | $39.39M | $32.96M | $6.11M | $-941.00K | $-9.57M | $-28.64M | $-18.72M | $-37.40M | $36.30M | $-277.56M | $-277.27M | $-255.46M | $-63.67M | $-63.67M | $-243.95M | $-60.99M | $-60.99M | $-60.99M | $-60.99M |
| Total Equity | $38.45M | $32.03M | $5.17M | $-1.88M | $-10.51M | $-29.57M | $-19.66M | $-38.34M | $37.46M | $-276.46M | $-276.22M | $-254.68M | $-63.67M | $-63.67M | $-243.95M | $-60.99M | $-60.99M | $-60.99M | $-60.99M |
| Total Liabilities and Stockholders Equity | $498.55M | $490.72M | $441.72M | $460.19M | $471.17M | $470.19M | $483.27M | $462.13M | $464.75M | $352.03M | $335.20M | $359.54M | $89.88M | $89.88M | $-243.95M | $84.43M | $84.43M | $84.43M | $84.43M |
| Minority Interest | $-932.00K | $-935.00K | $-937.00K | $-937.00K | $-940.00K | $-930.00K | $-939.00K | $-940.00K | $1.16M | $1.10M | $1.06M | $777.00K | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $498.55M | $490.72M | $441.72M | $460.19M | $471.17M | $470.19M | $483.27M | $462.13M | $464.75M | $352.03M | $335.20M | $359.54M | $89.88M | $89.88M | $-243.95M | $84.43M | $84.43M | $84.43M | $84.43M |
| Total Investments | $14.43M | $16.62M | $1.94M | $1.72M | $2.42M | $2.57M | $2.60M | $2.70M | $2.92M | $3.48M | $3.06M | $3.22M | $615.00K | $615.00K | $4.08M | $347.50K | $347.50K | $347.50K | $347.50K |
| Total Debt | $289.92M | $288.32M | $285.12M | $285.94M | $253.86M | $257.52M | $268.73M | $253.37M | $218.65M | $477.18M | $452.35M | $454.52M | $113.63M | $113.63M | $113.63M | $105.11M | $105.11M | $105.11M | $105.11M |
| Net Debt | $272.36M | $276.78M | $262.09M | $242.93M | $226.64M | $219.97M | $203.09M | $181.25M | $118.45M | $469.49M | $444.75M | $450.29M | $112.57M | $112.57M | $115.67M | $104.60M | $104.60M | $104.60M | $104.60M |
Annual Cash Flow
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Net Income | $42.54M | $-100.86M | $-10.45M | $-17.01M |
| Depreciation and Amortization | $16.84M | $15.11M | $16.48M | $16.47M |
| Deferred Income Tax | $10.17M | $13.71M | $11.30M | $7.04M |
| Stock Based Compensation | $- | $-8.40M | $-15.03M | $-15.50M |
| Change in Working Capital | $-25.63M | $-34.80M | $14.13M | $34.32M |
| Accounts Receivables | $-16.58M | $-21.26M | $1.89M | $6.74M |
| Inventory | $-32.69M | $-20.54M | $-898.00K | $-1.71M |
| Accounts Payables | $14.21M | $32.83M | $11.79M | $32.64M |
| Other Working Capital | $9.43M | $-25.84M | $1.35M | $-3.35M |
| Other Non Cash Items | $-29.82M | $152.55M | $54.49M | $42.98M |
| Net Cash Provided by Operating Activities | $14.11M | $37.30M | $70.92M | $68.29M |
| Investments in Property Plant and Equipment | $-20.61M | $-24.52M | $-17.92M | $-19.70M |
| Acquisitions Net | $- | $794.00K | $- | $- |
| Purchases of Investments | $- | $- | $-200.00M | $- |
| Sales Maturities of Investments | $- | $- | $- | $- |
| Other Investing Activities | $-8.22M | $28.00K | $200.83M | $7.63M |
| Net Cash Used for Investing Activities | $-28.83M | $-23.70M | $-17.09M | $-12.07M |
| Debt Repayment | $3.53M | $-360.00K | $-19.58M | $-30.66M |
| Common Stock Issued | $- | $- | $5.88M | $- |
| Common Stock Repurchased | $- | $-45.00M | $- | $- |
| Dividends Paid | $- | $- | $- | $- |
| Other Financing Activities | $-17.16M | $103.40M | $-20.93M | $-16.28M |
| Net Cash Used Provided by Financing Activities | $-13.63M | $58.04M | $-40.51M | $-46.95M |
| Effect of Forex Changes on Cash | $-760.00K | $-3.76M | $-11.13M | $-10.07M |
| Net Change in Cash | $-29.11M | $67.88M | $2.19M | $-802.00K |
| Cash at End of Period | $43.00M | $72.11M | $4.23M | $2.04M |
| Cash at Beginning of Period | $72.11M | $4.23M | $2.04M | $2.84M |
| Operating Cash Flow | $14.11M | $37.30M | $70.92M | $68.29M |
| Capital Expenditure | $-31.57M | $-24.52M | $-17.92M | $-19.70M |
| Free Cash Flow | $-17.47M | $12.78M | $53.00M | $48.59M |
Cash Flow Charts
| Breakdown | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $8.19M | $26.95M | $6.62M | $10.43M | $22.58M | $-6.92M | $16.45M | $-46.29M | $-36.92M | $-608.00K | $-17.04M | $9.45M | $-969.00K | $8.66M | $-27.58M | $-4.25M | $-4.25M | $-4.25M | $-4.25M |
| Depreciation and Amortization | $4.98M | $4.32M | $3.71M | $4.46M | $4.01M | $4.87M | $3.50M | $1.75M | $4.46M | $4.37M | $4.54M | $4.61M | $3.91M | $4.39M | $3.56M | $4.12M | $4.12M | $4.12M | $4.12M |
| Deferred Income Tax | $3.23M | $10.98M | $2.26M | $-934.00K | $7.81M | $-2.37M | $5.67M | $7.36M | $3.57M | $882.00K | $1.89M | $10.60M | $-751.00K | $-4.39M | $5.84M | $1.76M | $1.76M | $1.76M | $1.76M |
| Stock Based Compensation | $- | $-28.07M | $- | $- | $- | $- | $- | $73.92M | $3.87M | $-1.47M | $719.00K | $-20.95M | $5.67M | $-1.21M | $1.47M | $- | $- | $- | $- |
| Change in Working Capital | $21.23M | $-6.99M | $-9.46M | $-12.43M | $-6.85M | $-2.10M | $-4.26M | $1.37M | $-30.66M | $-10.96M | $5.45M | $23.00M | $-20.03M | $-10.80M | $21.97M | $8.58M | $8.58M | $8.58M | $8.58M |
| Accounts Receivables | $602.00K | $-9.70M | $11.75M | $-3.56M | $-9.23M | $-9.37M | $5.57M | $-6.99M | $-6.01M | $-10.93M | $2.67M | $-18.64M | $1.12M | $-1.90M | $21.30M | $1.69M | $1.69M | $1.69M | $1.69M |
| Inventory | $2.17M | $3.90M | $-813.00K | $-9.84M | $-1.91M | $-1.11M | $-19.83M | $-5.01M | $-9.75M | $-7.28M | $1.51M | $-1.73M | $-8.62M | $-42.00K | $9.49M | $-428.25K | $-428.25K | $-428.25K | $-428.25K |
| Accounts Payables | $16.73M | $10.01M | $-15.33M | $-18.59M | $6.15M | $9.83M | $16.81M | $43.80M | $-33.11M | $17.44M | $4.70M | $24.57M | $2.81M | $-8.39M | $-7.20M | $8.16M | $8.16M | $8.16M | $8.16M |
| Other Working Capital | $1.73M | $-11.20M | $-5.06M | $19.57M | $-1.87M | $-1.46M | $-6.81M | $-30.43M | $18.22M | $-10.18M | $-3.44M | $18.79M | $-15.34M | $-471.00K | $-1.63M | $-838.25K | $-838.25K | $-838.25K | $-838.25K |
| Other Non Cash Items | $9.76M | $13.24M | $-22.00K | $-9.48M | $-21.79M | $16.48M | $-15.02M | $-12.12M | $50.65M | $14.35M | $14.24M | $14.73M | $14.24M | $12.21M | $13.31M | $6.87M | $6.87M | $6.87M | $6.87M |
| Net Cash Provided by Operating Activities | $47.39M | $20.43M | $3.11M | $-7.94M | $5.76M | $9.96M | $6.33M | $25.99M | $-5.04M | $6.56M | $9.79M | $41.42M | $2.06M | $8.87M | $18.57M | $17.07M | $17.07M | $17.07M | $17.07M |
| Investments in Property Plant and Equipment | $-7.68M | $-7.86M | $-4.86M | $-8.53M | $-7.43M | $-11.60M | $-4.02M | $-7.69M | $-7.22M | $-6.37M | $-3.24M | $-6.68M | $-4.77M | $-3.66M | $-2.81M | $-4.92M | $-4.92M | $-4.92M | $-4.92M |
| Acquisitions Net | $- | $- | $- | $33.00K | $-36.00K | $- | $- | $768.00K | $- | $26.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $211.00K | $-19.00K | $-163.00K | $199.00K | $1.00K | $2.69M | $-136.00K | $796.00K | $-1.73M | $26.00K | $-1.45M | $827.00K | $-1.00K | $-919.00K | $920.00K | $4.94M | $4.94M | $4.94M | $4.94M |
| Net Cash Used for Investing Activities | $-7.47M | $-7.88M | $-5.03M | $-8.29M | $-7.46M | $-8.91M | $-4.16M | $-6.90M | $-7.22M | $-6.35M | $-3.24M | $-5.86M | $-4.77M | $-4.58M | $-1.89M | $10.75K | $10.75K | $10.75K | $10.75K |
| Debt Repayment | $-19.16M | $-16.73M | $-11.70M | $- | $-1.87M | $-19.15M | $-3.88M | $-39.02M | $-11.51M | $9.57M | $7.29M | $-30.81M | $7.33M | $- | $413.00K | $-175.00K | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-794.00K | $-156.00K | $- | $- | $- | $- | $- | $-45.00M | $-45.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $-300.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-9.93M | $-8.12M | $-6.89M | $27.92M | $-3.49M | $-6.88M | $-6.28M | $26.30M | $118.80M | $-3.98M | $-4.09M | $-8.09M | $-2.77M | $-666.00K | $-5.91M | $-37.47M | $-31.76M | $-31.76M | $-31.76M |
| Net Cash Used Provided by Financing Activities | $-29.88M | $-25.01M | $-18.59M | $27.92M | $-5.36M | $-26.03M | $-10.16M | $-58.02M | $107.28M | $5.59M | $3.20M | $-38.91M | $4.56M | $-666.00K | $-5.50M | $-31.76M | $-31.76M | $-31.76M | $-31.76M |
| Effect of Forex Changes on Cash | $-4.03M | $964.00K | $539.00K | $4.10M | $-3.27M | $-3.11M | $1.52M | $10.85M | $-2.52M | $-5.70M | $-6.38M | $1.10M | $-2.00M | $-1.15M | $-9.08M | $14.48M | $14.48M | $14.48M | $14.48M |
| Net Change in Cash | $6.02M | $-11.49M | $-19.97M | $15.79M | $-10.34M | $-28.09M | $-6.47M | $-28.08M | $92.50M | $96.00K | $3.37M | $-2.24M | $-149.00K | $2.47M | $2.11M | $-200.50K | $-200.50K | $-200.50K | $-200.50K |
| Cash at End of Period | $17.56M | $11.54M | $23.03M | $43.00M | $27.21M | $37.55M | $65.64M | $72.11M | $100.19M | $7.70M | $7.60M | $4.23M | $6.47M | $6.62M | $4.15M | $510.50K | $510.50K | $510.50K | $510.50K |
| Cash at Beginning of Period | $11.54M | $23.03M | $43.00M | $27.21M | $37.55M | $65.64M | $72.11M | $100.19M | $7.70M | $7.60M | $4.23M | $6.47M | $6.62M | $4.15M | $2.04M | $711.00K | $711.00K | $711.00K | $711.00K |
| Operating Cash Flow | $47.39M | $20.43M | $3.11M | $-7.94M | $5.76M | $9.96M | $6.33M | $25.99M | $-5.04M | $6.56M | $9.79M | $41.42M | $2.06M | $8.87M | $18.57M | $17.07M | $17.07M | $17.07M | $17.07M |
| Capital Expenditure | $-7.68M | $-7.86M | $-4.86M | $-8.53M | $-7.43M | $-11.60M | $-4.02M | $-7.69M | $-7.22M | $-6.37M | $-3.24M | $-6.68M | $-4.77M | $-3.66M | $-2.81M | $-4.92M | $-4.92M | $-4.92M | $-4.92M |
| Free Cash Flow | $39.71M | $12.57M | $-1.76M | $-16.47M | $-1.67M | $-1.64M | $2.31M | $18.30M | $-12.26M | $185.00K | $6.56M | $34.74M | $-2.71M | $5.21M | $15.76M | $12.15M | $12.15M | $12.15M | $12.15M |
Procaps Group S.A Dividends
Explore Procaps Group S.A's dividend history, including dividend yield, payout ratio, and historical payments.
Procaps Group S.A News
Read the latest news about Procaps Group S.A, including recent articles, headlines, and updates.
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that the first patient has been dosed in Part 2 of the Phase 2 DENALI clinical trial (NCT05128825) of azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). As previously disclosed, the Company aligned with the U.S. Food and Drug Administration (FDA) on the design of DENALI Part 2, which allows for seamless enrollment in the two parts of the trial: Part 2a is designed to confirm the primary dose-of-interest with a target enrollment of approximately 30 patients at each of two dose levels: 400mg QD 5:2 and 300mg QD 5:2 (intermittent daily dosing on a five days on, two days off dosing schedule).
Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership
New Investors Take Over the Strategic Leadership as Headquarters Move to Bogotá, Marking the Start of a New Chapter of Growth, Execution, and Transformation under Enhanced Governance
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Corcept Therapeutics Incorporated's relacorilant met the primary endpoint in the phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, boosting shares by over 90% the very same day. Upcoming catalysts include full trial data release at a medical conference, NDA filing in Q3 2025, and MAA submission to the EMA shortly afterward. Relacorilant also targets hypercortisolism with endogenous Cushing's Syndrome patients with an FDA PDUFA date set for December 30, 2025, based on positive GRACE, GRADIENT, and phase 2 study data.
Procaps Group Receives Delisting Notice From Nasdaq
MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that the Company received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) that it has determined to delist the Company's ordinary shares on Nasdaq. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules 5250(c)(1) and 5250(c)(2) for failing to file periodic and interim financial reports. As a result of the forgoing, the Company's ordinary shares are expected to commence trading on the Expert Market operated by the OTC Markets Group, Inc. (“OTC”), commencing on February 4, 2025.
Procaps Group Receives Additional Delinquency Letter
MIAMI and BARRANQUILLA, Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that, as anticipated, on December 31, 2024, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) of an additional filing delinquency relating to the Company's interim financial statements for the period ended June 30, 2024.
Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team.
Procaps Group Announces Financing, Shareholders Agreement and Board Updates
MIAMI and BARRANQUILLA, Colombia , Dec. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced the successful execution of key strategic transactions and governance updates aimed at strengthening its financial position and supporting long-term growth objectives.
Procaps Receives Nasdaq Listing Determination; To Request Hearing and Further Stay Pending Hearing
MIAMI and BARRANQUILLA, Colombia, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), announced today that, on November 13, 2024, the Company received formal notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company's failure to timely file the Form 20-F for the fiscal year ended December 31, 2023 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (the “SEC”), the Company no longer satisfied Nasdaq Listing Rule 5250(c)(1) (the “Filing Rule”) and its securities are therefore subject to suspension and delisting unless the Company timely requests a hearing before and a further stay of any suspension action at least pending the ultimate conclusion of the hearings process from the Nasdaq Hearings Panel (the “Panel”).
Procaps Issues Shareholder Letter Update
MIAMI and BARRANQUILLA, Colombia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, providing critical updates on the Company's ongoing independent investigation, financial restatement, governance enhancements, and commitment to long-term stability.
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024
COPENHAGEN, Denmark, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced initial data showing signs of clinical activity in heavily pre-treated patients with platinum-resistant ovarian cancer (PROC) treated with TransCon IL-2 β/γ in combination with chemotherapy in its ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β/γ. First results will be shared in Poster 762P at ESMO 2024, the annual meeting of the European Society of Medical Oncology being held in Barcelona from September 13-17, 2024.
Procaps Issues Shareholder Letter
MIAMI and BARRANQUILLA, Colombia, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today issued the below letter to shareholders from José Antonio Vieira, CEO of Procaps, addressing the current state of the business and outlining key strategic priorities for the Company.
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
The SON-1010 studies have together enrolled 61 subjects, to date, as dose escalation continues in SB101 and SB221 at higher levelsPatients have received up to 25 cycles of SON-1010 as monotherapy and 10 cycles of SON-1010 with atezolizumab (Tecentriq®) without dose-limiting toxicity at any dose levelCytokine data reveals about 10-fold extended half-life for SON-1010 compared with rhIL-12 that induces prolonged and controlled IFNγ responses, with no evidence of cytokine release syndrome at any doseClinical benefit was seen at four months post-initiation of dosing in 35% of evaluable patients (8/23) with advanced solid tumors PRINCETON, NJ / ACCESSWIRE / May 20, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the safety of SON-1010 dosing has been formally reviewed in both of the current Phase 1 clinical trials and the Company is now increasing the target dose of SON-1010 during dose escalation. SON-1010 is a proprietary version of recombinant human interleukin-12 (rhIL-12), configured using Sonnet's Fully Human Albumin Binding (FHAB®) platform, which extends the half-life and activity of the IL-12 component due to binding native albumin in the serum and targets the tumor microenvironment (TME) by strongly binding gp60 and Secreted Protein Acidic and Rich in Cysteine (SPARC). SB101 is a Phase 1 multiple-ascending dose (MAD) trial in adult patients with advanced solid tumors (NCT05352750) that commenced in Q2 2022 and is currently enrolling the sixth dose cohort. SB221 is a Phase 1b/2a dose-escalation and proof-of-concept study of the combination of SON-1010 with atezolizumab (in collaboration with Genentech, a member of the Roche Group), in a study focused on platinum-resistant ovarian cancer (PROC) (NCT05756907) that started in Q4 2023, now enrolling the fourth dose cohort. In addition, SON-1010 was studied in SB102, which was a Phase 1 single-ascending dose (SAD) trial in healthy volunteers (NCT05408572) that started in Q3 2022; the results were recently published (Kenney, et al, Frontiers in Immunology, 2024).Safety in both of the active cancer trials has been reviewed by their respective Safety Review Committees at each step during dose escalation. Both trials use a ‘desensitizing' first dose to take advantage of the known tachyphylaxis with rhIL-12, which minimizes toxicity and allows higher maintenance doses. No dose-limiting toxicities or related serious adverse events have occurred to date. The safety and toxicity profile that has developed is typical for a Phase 1 oncology trial, with the majority of adverse events (AEs) being reported as mild. All have been transient, with no evidence of cytokine release syndrome. Of the 25 cancer patients dosed to date and evaluable for follow-up at this latest cutoff, 15 (60%) had stable disease at their first follow-up scan, 8 of whom were progressing at study entry. At four months follow-up, 8 of 23 evaluable patients remained stable at the second CT scan, suggesting clinical benefit of SON-1010 in 35% of the patients."We have now dosed 18 cancer patients at increasing SON-1010 drug levels in the SB101 study, completed dosing in 31 healthy volunteers in SB102, and are rapidly filling the dose-escalation cohorts with 12 subjects enrolled in the first four cohorts of the SB221 combination study," said Richard Kenney, M.D., Sonnet's Chief Medical Officer. "The overall safety and toxicity profile for SON-1010, primarily including local reactions, headache, myalgia, and fatigue, mimics the published experience with rhIL-12, which prompted us to raise the target dose to enhance potential efficacy. The SB102 study allowed us to generate clean data for the pharmacokinetic (PK) and pharmacodynamic (PD) analyses, enabling simulation of the effect of multiple doses with the help of a continual reassessment model of PK and PD. This modeling suggests target-mediated drug disposition (TMDD), which supports the mechanism of the FHAB being directed to tumor tissue. The combination of SON-1010 with atezolizumab may benefit from the ability of IL-12 to turn ‘cold' tumors ‘hot', which upregulates the amount of PD-L1 in the TME."One patient with progressive endometrial sarcoma receiving SON-1010 monotherapy in SB101 had stable disease (SD) for almost 2 years before progressing - her ascites had resolved and tumors had shrunk at one point but she never reached a partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) rules. Cytokine analysis following each dose in that study revealed controlled and prolonged induction of interferon gamma (IFNγ) that peaked at 24 to 48 hours and returned to baseline within 2 to 4 weeks. A small increase in IL-10 was observed with each dose as expected in response to IFNγ. There was either a minimal or no signal for IL-1β, IL-6, IL-8, and TNFα, and there was no indication of any potential for cytokine release syndrome (CRS) at these doses. One patient in Part 1 of SB221 with uterine sarcomas received 8 cycles of the SON-1010/atezolizumab combination therapy every 3 weeks before progressing; another two have received 8 and 10 cycles, respectively, and are continuing on the study. The stable AE profiles despite dose escalation led us to reevaluate the target dose, so the Company has added groups in both studies to evaluate 1200 ng/kg SON-1010 as a maintenance dose (the molar equivalent of 800 ng/kg rhIL-12). Finally, Part 2 of the SB221 combination study has been trimmed to remove the monotherapy arm."The findings to date in these two trials represent significant progress for the SON-1010 molecule", said Robert Wenham, M.D., Chair, Department of GYN Oncology at Moffitt Cancer Center and the Lead Principal Investigator for SB221. "Multiple strategies to present IL-12 safely have been tried over the past two decades with little evidence of improved tolerability in humans, yet the preclinical models continue to suggest that induction of IFNγ in the TME can activate an effective anti-tumor response. This also results in the local induction of PD-L1. Adding a cohort to increase the target MTD of SON-1010, an extended PK molecule that is concentrated in the TME, is the right approach at this stage. This will provide a chance to study the safety of SON-1010 monotherapy in SB101, and then in combination with atezolizumab in SB221, along with the clinical effect of the combination on PROC in a limited set of subjects in the expansion cohort later this year. Defining the best dose for SON-1010 is required to allow a direct randomized comparison of the strategy with the standard of care therapy in Part 2.""We are very pleased with the data we are seeing at these higher dose levels of SON-1010, with safety and tolerability being well within expected levels, as well as displaying SON-1010 extended PK/PD, tumor targeting, and clinical activity during treatment," said Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. "Research on rhIL-12 in humans has been hindered by toxicity for decades. We believe that the IL-12 component in SON-1010 is presented in a way that is safer, due to the longer half-life, and it is concentrated in the tumor, due to the recurrent binding of the FHAB-associated albumin to SPARC in the TME. It is important to note that many of these patients have been fighting their cancers for a very long time and have exhausted all approved treatment regimens available to them, so seeing tumor shrinkage at any dose is both difficult to achieve and encouraging for future results. We are excited to continue testing the impact of SON-1010 in combination with atezolizumab at these higher dose levels in patients with PROC, who represent a significant unmet medical need, and we expect to have a further update early next year."About SON-1010SON-1010 is a candidate immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3. This was selected to bind both at normal pH, as well as at the acidic pH typically found in the TME. The FHAB technology targets tumor and lymphatic tissue, providing a mechanism for dose sparing and an opportunity to improve the safety and efficacy profile of not only IL-12, but a variety of potent immunomodulators that can be added using the platform. Interleukin-12 can orchestrate a robust immune response to many cancers and pathogens. Given the types of proteins induced in the TME, such as the Secreted Protein and Rich in Cysteine (SPARC) and glycoprotein 60 (GP60), several types of cancer such as non-small cell lung cancer, melanoma, head and neck cancer, sarcoma, and some gynecological cancers are particularly relevant for this approach. SON-1010 is designed to deliver IL-12 to local tumor tissue, turning ‘cold' tumors ‘hot' by stimulating IFNγ, which activates innate and adaptive immune cell responses and increases the production of Programed Death Ligand 1 (PD-L1) on tumor cells.About the SB101 Phase 1 TrialThis first-in-human study is primarily designed to evaluate the safety of multiple ascending doses of SON-1010 in cancer patients and will be conducted at several sites across the United States. While the optimal dose is unknown at this stage, the potential to target tumors, the extended PK mechanism and our preclinical data suggest the therapeutic dose may be lower compared to native human IL-12. The study, utilizing a standard 3+3 oncology design in at least five cohorts, should establish the MTD and the recommended Phase 2 dose (RP2D) using monthly subcutaneous injections of SON-1010. The primary endpoint explores the safety and tolerability of SON-1010, with key secondary endpoints intended to measure pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity. This study will form the basis for potential combinations with other types of immunotherapies and the future development of bispecific candidates using the FHAB platform.About the SB221 Phase 1b/2a TrialSB221 is a global Phase 1b/2a multicenter, dose-escalation and randomized proof-of-concept study to assess the safety, tolerability, PK, PD, and efficacy of SON-1010 administered subcutaneously (SC), either alone or in combination with atezolizumab given intravenously (IV). The study is designed in Part 1 to rapidly establish the maximum tolerated dose (MTD) of the combination in patients with advanced solid tumors at the lower dose levels. The focus shifts to PROC at higher dose levels using small dose-escalation groups with expansion of the dataset at the recommended Phase 2 dose (RP2D). This would be followed in Part 2 by an assessment in patients with PROC of the potential for improved efficacy of the combination versus the standard of care. Both companies look forward to this collaboration as an opportunity to improve outcomes for patients with ovarian cancer.About Sonnet BioTherapeutics Holdings, Inc.Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines.Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the outcome of the Company's clinical trials, the Company's cash runway, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or the Company's financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.Sonnet BioTherapeutics Investor ContactJack YauchSolebury Strategic Communications862-754-1024jyauch@soleburystrat.comSOURCE: Sonnet BioTherapeutics Holdings, Inc.
Procaps Group – Notice to Shareholders
MIAMI & BARRANQUILLA, Colombia.--(BUSINESS WIRE)--Dear Shareholders, We became aware on Saturday, January 13, 2024, that the online voting instructions related to the upcoming General Meeting of Shareholders of the Company scheduled for January 22, 2024, were incorrect. Notwithstanding the Company's diligent review of all relevant materials, a third party unilaterally included on the online version an inaccurate statement that the Board of Directors of the Company had recommended a vote in favo.
Procaps Group and Genomma Lab Announce a Strategic Agreement to Manufacture and Market Softgel Products in Latin America
Agreement Combines Procaps Oral Delivery System Technology and Manufacturing with Genomma's Strategic Marketing and Distribution Footprint BARRANQUILLA, Colombia and MEXICO CITY and MIAMI , Nov. 29, 2023 /PRNewswire/ -- Procaps Group (NASDAQ: PROC) ("Procaps"), a leading integrated international healthcare and pharmaceutical services company, and Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB; "Genomma"), the leading pharmaceutical and personal care company in Latin America, today announced a strategic agreement to develop, manufacture and market five Softgel products within Latin America.
Procaps Group to Participate at CPHI Barcelona 2023
MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)--Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today that it will participate at the CPHI Barcelona 2023, that will take place from October 24th to October 26th, continuing with our two-decade presence in the conference. We welcome you to learn more on our specialized technologies and capabilities such as our novel oral delivery system formulations, gummies, development o.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for PROC.